Making Penumbral Imaging a Reality - MR Perfusion Stroke Management Solution
Clinical Sales Manager
Subspecialty and Expertise in Radiology
NeuroRadiology - Brain Imaging specialists with a focus on MR, CTp, Tumor Perfusion post processing GROUNDBREAKING software. The DEFUSE study is written by the STANFORD team (Dr Albers and Dr Olivot). They find that a Tmax between 4 and 6 seconds is optimal for early identification of hypoperfused tissue. It is a very interesting map because TMax thresholds exist and are validated by the study, as opposed to MTT, TTP, CBV, CBF.
Our software pre-set thresholding of the TMax maps (on 4 or 6 seconds) permits the user to quickly estimate the hypoperfused areas, without user input, unless the user wishes to use the manual feature. Our software is the only system that offers a TMAX map that is cleared by the FDA, on all brain levels.
Olea perfusion software Computes Instant Perfusion maps utilizing Automatic AIF selection and Deconvolution- Instant multiparametric analysis presents all series simultaneously in a single dashboard view in just few seconds. Instant calculation of Lesion and Penumbra volumes and Mis Match Ratio. Identify/recognize TIA's instantly. Configured to work with all MR scanners and PACS systems- therefore providing a standard across multi - platform imaging centers. Fast, Accurate and easy to use!
Clinical, Academic, or Industry Experience
Brain Imaging Specialist with a focus on Stroke and Tumor diagnosis/treatment management
Clinical, academic, research, or business interests within radiology
To provide Neuroradiologists, Neurointerventionalists, MR techs, Hospital Stroke centers, and Imaging Centers with the most advanced stroke and tumor MR Perfusion post processing sw that has HD image quality, ease of use, Auto AIF- instant perfusion/diffusion maps presented in a single view dashboard,1 click- lesion and hypoperfused tissue volume calculations and mismatch ratio in cc's, all in less than 2 minutes to make the diagnosis.
Publications, Honors, and Awards
NIH/NINDS scientists, led by Dr. Steven Warach, are using PerfScapeTM and NeuroScapeTM, Olea Medical’s FDA-cleared software, to compare mismatch calculations produced with the Olea software versus qualitative evaluations of mismatch using MRI scanner provided images only.
In a proof of concept study, Warach and colleagues reported that processing acute MRI studies is feasible using the Olea software.